Dave Levitan

Patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer who received nivolumab along with ipilimumab had high response rates and improved survival outcomes compared with those who received nivolumab alone.

Neoadjuvant treatment with dabrafenib and trametinib offered significantly improved event-free survival over standard of care in high-risk melanoma patients.

Some patients with unresectable or metastatic melanoma who receive immunotherapy and who continue therapy after progression have decreased tumor burden, and survival is improved when the therapy is continued as well, according to a new pooled analysis.

The novel agent prexasertib showed promising activity and was reasonably well tolerated in a phase II study of high-grade, heavily pretreated, BRCA wild-type serous ovarian carcinoma.

Adding abiraterone plus prednisone to ADT improves patient-reported outcomes and quality of life in patients with metastatic castration-naive prostate cancer.

Treatment with hyperthermic intraperitoneal chemotherapy along with cytoreductive surgery resulted in better survival outcomes than surgery alone in patients with stage III epithelial ovarian cancer, according to a new study.

Bladder cancer patients with tumors smaller than 1 cm could be classified as “very-low-risk,” with recurrences that could arise after the 5-year surveillance period.

Continuing letrozole therapy after 5 years of aromatase inhibitor therapy did not worsen quality-of-life measures in patients with HR-positive breast cancer.

The EGFR tyrosine kinase inhibitor osimertinib showed promising efficacy and manageable toxicity in patients with advanced NSCLC and CNS metastases.

Metastatic melanoma patients treated with pembrolizumab who achieve a complete response can maintain those responses, even after discontinuation of therapy.

BCR-ABL1 transcript levels at time points within the first year of therapy for CML can best predict the achievement of a deep molecular response.

An individual risk–based approach could identify more people eligible for lung cancer screening, and thus prevent more early deaths, compared with USPSTF criteria.

The combination of exosomal RNA and cell-free DNA improved the sensitivity of blood-based liquid biopsy for EGFR mutation detection in non–small-cell lung cancer compared with standard circulating tumor DNA.

Educational strategies including pamphlets and recommendations from family physicians and support from a specialist can improve bone care in men with prostate cancer undergoing androgen deprivation therapy.

Dual HER2 blockade with lapatinib and trastuzumab plus AI therapy was more effective than trastuzumab plus AI alone in HER2+, HR+ metastatic breast cancer.

A study found familial clustering of urothelial cancers, with increased risk of bladder cancer and others, in first- and second-degree relatives of these patients.

Toxicities from buparlisib make it a poor option for patients with HR-positive, HER2-negative advanced breast cancer who progressed on mTOR inhibitor therapy.

The use of bipolar androgen therapy was safe and resulted in responses to enzalutamide in metastatic castration-resistant prostate cancer patients after initial therapy.

Cardiac effects of pertuzumab and trastuzumab following chemotherapy in the neoadjuvant setting were limited for HER2-positive breast cancer patients.

The FDA has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer.

Patients with metastatic colorectal cancer and high expression of VEGF-D garner more benefit from the VEGFR-2 antibody ramucirumab than those with low VEGF-D expression, according to a new study.

The addition of pazopanib to paclitaxel failed to improve outcomes over paclitaxel alone in women with persistent or recurrent epithelial ovarian cancer.

A large meta-analysis found that current and former smoking status was associated with poorer colorectal cancer prognosis compared with never smoking, and that smoking cessation may improve survival over those who continue to smoke.

The PARP inhibitor talazoparib significantly increased progression-free survival over physician’s choice of therapy in a randomized phase III trial of patients with advanced breast cancer and a germline BRCA mutation.

The immune checkpoint inhibitor avelumab showed promising antitumor activity and a manageable toxicity profile in patients with platinum-refractory metastatic urothelial carcinoma, according to a new analysis.

Treatment with anamorelin significantly increased lean body mass and improved anorexia symptoms in patients with advanced non–small-cell lung cancer, according to a new study conducted in Japan.

A study found that circulating tumor cells are predictive of late recurrence in patients with hormone receptor–positive, HER2-negative early breast cancer.

An antibody–drug conjugate known as sacituzumab govitecan demonstrated significant clinical activity in heavily pretreated patients with relapsed/refractory metastatic triple-negative breast cancer, according to a new study.

Adding vistusertib to fulvestrant failed to demonstrate a benefit over everolimus in patients with ER-positive advanced or metastatic breast cancer.

Adding trastuzumab to adjuvant chemotherapy did not result in improved rates of invasive disease-free survival in patients with early-stage breast cancer and low levels of HER2 expression, according to a new study.